Science
Cristiane Bergerot: Mapping TP53 Alterations and Y220C Mutations in Advanced Breast Cancer
Cristiane Bergerot/ X

Cristiane Bergerot: Mapping TP53 Alterations and Y220C Mutations in Advanced Breast Cancer

Cristiane Bergerot, Former Postdoc Fellow and Research Consultant at City of Hope, shared on X:

“TP53 alterations are common in advanced breast cancer, but the rare, potentially targetable Y220C mutation highlights emerging opportunities for precision oncology.

–

Title: TP53 Genomic Alterations Including Targetable Y220C Mutation in Advanced Breast Cancer

Authors: Nicole A. Casasanta, Adriana Kahn, Neal Fischbach, Dean Pavlick, Patricia LoRusso, Ethan S. Sokol, Ryon Graf, Julia C.F. Quintanilha, Gerald Li, Jeffrey S. Ross, Maryam B. Lustberg

Read the full article.

–

Study goal:

  • To determine the prevalence of TP53 Y220C and characterize associated genomic alternations in advanced breast cancer

Key findings:

  • 23760 patients underwent genomic profiling
  • 53% had TP53 alternations
  • Only 1.1% harbored the potentially targetable Y220C mutation
  • Y220C was frequently identified in triple-negative breast cancer.”

You can also read:

Hesham Elghazaly and the Vision of One World Against Cancer

Cristiane Bergerot: Mapping TP53 Alterations and Y220C Mutations in Advanced Breast Cancer

Adriana Kahn Breast Cancer cancer Cristiane Bergerot Dean Pavlick Ethan S Sokol Gerald Li Jeffrey S. Ross Julia C.F. Quintanilha Maryam B. Lustberg Neal Fischbach Nicole A. Casasanta OncoDaily Oncology Patricia LoRusso Ryon Graf TNBC TP53 TP53 alterations triple-negative breast cancer Y220C Y220C mutation